Renovo Rx, Inc. RNXT
We take great care to ensure that the data presented and summarized in this overview for RenovoRx, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RNXT
View all-
Bank Of The West975KShares$984,7500.27% of portfolio
-
Geode Capital Management, LLC Boston, MA236KShares$238,1050.0% of portfolio
-
Adar1 Capital Management, LLC Austin, TX197KShares$199,2220.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA141KShares$142,9010.0% of portfolio
-
Nixon Peabody Trust CO Boston, MA97.2KShares$98,1360.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny76.8KShares$77,5820.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny64.9KShares$65,5490.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA49.2KShares$49,7240.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il37.8KShares$38,1340.0% of portfolio
-
Kestra Advisory Services, LLC35.5KShares$35,8750.0% of portfolio
Latest Institutional Activity in RNXT
Top Purchases
Top Sells
About RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Insider Transactions at RNXT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 26
2024
|
Ramtin Agah Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
40,983
+46.34%
|
-
|
|
Jan 26
2024
|
Robert J. Spiegel Director |
BUY
Open market or private purchase
|
Direct |
40,983
+50.0%
|
-
|
|
Jan 26
2024
|
Shaun Bagai Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
40,983
+12.29%
|
-
|
|
Jan 26
2024
|
Kirsten Angela Macfarlane Director |
BUY
Open market or private purchase
|
Direct |
40,983
+50.0%
|
-
|
|
Jan 26
2024
|
Laurence Marton Director |
BUY
Open market or private purchase
|
Direct |
8,196
+19.59%
|
-
|
|
Oct 03
2023
|
Angela Nelms Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
1,100
+46.05%
|
$1,100
$1.05 P/Share
|
|
Nov 03
2022
|
Laurence Marton Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,438
+50.0%
|
$25,438
$1.7 P/Share
|
|
Jun 07
2022
|
Ramtin Agah Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
5,182
+44.45%
|
$5,182
$1.93 P/Share
|
|
May 19
2022
|
Shaun Bagai Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,500
+2.14%
|
$11,000
$2.05 P/Share
|
|
Mar 16
2022
|
Ramtin Agah Chief Medical Officer |
BUY
Bona fide gift
|
Indirect |
975,000
+50.0%
|
-
|
|
Mar 16
2022
|
Ramtin Agah Chief Medical Officer |
SELL
Bona fide gift
|
Direct |
975,000
-99.87%
|
-
|
|
Aug 30
2021
|
Ramtin Agah Chief Medical Officer |
BUY
Conversion of derivative security
|
Direct |
1,295
+0.13%
|
-
|